Guo Y, Cai YQ, Cai ZL, et al. Differentiation of clinically benign and malignant breast lesions u sing dif fusion-weighted imaging[J].J Magn Reson Imaing, 2002, 16(2):172-178.
Woodhams R,Kakita S,Hata H.Identification of residual breast carcinoma following neoadjuvant chemotherapy:diffusion weighted imaging-comparison with contrast-enhanced MRI imaging and pathologic findings[J].Radiology,2010, 254(2):357-366.
[8]
Eisenhauer EA, Therasse P, Bogaerts J. New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].European Journal of Cancer,2009,(02):228-247.
[9]
Orel S.Who should have breast magnetic resonance imaging evaluation[J].Clin Oncol, 2008, 26(5):703-711.
[10]
Lee KC,Moffat BA, Schott AF,et al.Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy[J]. Clin Cancer Res, 2007, 13(2Pt 1):443-450.
[11]
吴在德,吴肇汉.外科学[M].8版.北京:人民卫生出版社,2008.
[12]
Chenevert TL,Stegman LD,Taylor JM,et al.Diffusion magnetic resonance imaginig:an early surrogate marker of therapeutic efficacy in brain tumors[J].J Natl Cancer Inst,2000,92(24):2029-2036.
[13]
Sharma U, Danishad KK, Seemu V, et al, Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant[J].NMR Biomed, 2009, 22(1); 104- 113.
[14]
Liu y,Bai R,Sun H, et al. Diffusion-weighted imaging in Predicting and monitoring the response of uterine cervical cancer to combined chemo radiation[J].Clin Radio,2009,64(11):1067-1074.
